Aug 2026
Effectiveness of RSV Prevention Strategies in US Infants: 2024-2025.
OBJECTIVE In 2023, 2 products, a long-acting monoclonal antibody (nirsevimab) and maternal respiratory syncytial virus (RSV) vaccination, were recommended in the United States to prevent severe RSV disease among infants in their first RSV season. Low uptake during the 2023 to 2024 RSV season limited effectiveness estim...
A. Payne, S. Battan-Wraith, S. E. Reese et al.
· Pediatrics · 0 citations